Seitz Michael, Stief Christian, Waidelich Raphaela
UroClinic München GbR - Campus Bogenhausen, Richard-Strauss-Strasse 82, 81679, Munich, Germany.
Department of Urology, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
BMC Infect Dis. 2017 Oct 16;17(1):685. doi: 10.1186/s12879-017-2789-7.
Acute uncomplicated cystitis (AUC) is a common ailment in the urological setting. Guidelines for urinary tract infections are based on large-scale multi-centre, epidemiological and international studies. The objective of this observational study was to establish whether the results of a multi-centre study on the resistance profile of Escherichia coli (E. coli) in patients with AUC could be directly applied to an urological practice in a major European city or whether there are divergences in the resistance profile.
An observational study was applied prospectively to 502 patients with AUC between January 2015 and January 2017). Personal data were anonymised. Exclusion criteria were the patient's age (<18) and treatment with an antibiotic in the week preceding examination.
The average age was 32 (range 18-56). The most commonly detected bacteria was E. coli with 86%, followed by Enterococcus faecalis with 10% and Klebsiella pneumoniae with 4%. Resistance tests showed E. coli to be highly sensitive to fosfomycin (99.2%), nitrofurantoin (98.1%) and cefpodoxime (92.9%). E. coli exhibited resistance to ciprofloxacin (CIP) in 15.1%, to trimethoprim/sulfamethoxazole (TRS) in 25.2% and to amoxicillin/clavulanic acid (AMC) in 34% of cases.
The comparison between data from this study and data from a multi-centre European (ECO-SENSI, ECO-SENSII and the 2014 update) showed relatively good sensitivity rates for fosfomycin and nitrofurantoin but significant differences in respect of resistance levels to TRS, CIP and AMC. AUC should therefore only be treated with TRS, CIP and AMC after a susceptibility test has been carried out.
急性单纯性膀胱炎(AUC)是泌尿外科常见疾病。尿路感染指南基于大规模多中心、流行病学及国际研究制定。本观察性研究的目的是确定一项关于AUC患者大肠埃希菌(大肠杆菌)耐药谱的多中心研究结果是否可直接应用于欧洲某大城市的泌尿外科实践,或者耐药谱是否存在差异。
2015年1月至2017年1月期间,对502例AUC患者进行前瞻性观察性研究。个人数据进行了匿名处理。排除标准为患者年龄(<18岁)及检查前一周内使用过抗生素。
平均年龄为32岁(范围18 - 56岁)。最常检测到的细菌是大肠杆菌,占86%,其次是粪肠球菌,占10%,肺炎克雷伯菌占4%。耐药试验显示,大肠杆菌对磷霉素(99.2%)、呋喃妥因(98.1%)和头孢泊肟(92.9%)高度敏感。在15.1%的病例中,大肠杆菌对环丙沙星(CIP)耐药,对甲氧苄啶/磺胺甲恶唑(TRS)耐药率为25.2%,对阿莫西林/克拉维酸(AMC)耐药率为34%。
本研究数据与欧洲多中心研究(ECO - SENSI、ECO - SENSII及2014年更新数据)的比较显示,磷霉素和呋喃妥因的敏感率相对较好,但在对TRS、CIP和AMC的耐药水平方面存在显著差异。因此,AUC仅应在进行药敏试验后使用TRS、CIP和AMC进行治疗。